RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src

Overexpression of EGFR is commonly seen in gastric cancer (GC). However, patients with GC show resistance to anti-EGFR treatments. RAS mutations are rare in GC and cannot explain de novo resistance to EGFR treatments. Therefore, it is particularly important to explore the mechanisms of resistance to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Zhang, Xiaomeng, Song, Yongxi, Song, Na, Zhang, Ye, Zhang, Lingyun, Wang, Yan, Wang, Zhenning, Qu, Xiujuan, Liu, Yunpeng
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5229171/
https://ncbi.nlm.nih.gov/pubmed/28123301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S110918
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados